MedDataX Logo

The Significance of Funguria in Hospitalized Patients

NCT ID: NCT00787085

Last Updated: 2008-11-07

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

919 participants

Study Classification

OBSERVATIONAL

Study Start Date

2001-09-30

Study Completion Date

2006-02-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This investigation is a epidemiologic case-control study of the risk factors associated with nosocomial funguria (fungi in the urine).

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

A recent large multi-center national surveillance survey of almost 5000 nosocomial (hospital based) urine isolates from medical intensive care units demonstrated that fungi comprised nearly 40% of urine isolates. Little is known about distinguishing fungi that cause colonization from those causing infection.

The objective of this study is to define the epidemiology of nosocomial funguria and natural history of patients that develop funguria while hospitalized.

Patients who may have eligible for this study will be identified from microbiology laboratory specimens at the Harbor-UCLA Medical Center and Cedars-Sinai Medical Center.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Urinary Tract Infections

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Funguria Epidemiology Urinary Tract Infections

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Case

Patients hospitalized with a urine or blood culture positive for fungi

No interventions assigned to this group

Control

Patients hospitalized with a urine culture negative for fungi

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients hospitalized at least 12 hours of any age (\< 1 day to \> 100 years of age) AND a urine or blood culture positive for fungi, OR urine culture negative for fungi (control group)

Exclusion Criteria

* Patients already surveyed for funguria during current hospitalization and patients already being followed for recognized funguria
Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

Sponsor Role collaborator

Cedars-Sinai Medical Center

OTHER

Sponsor Role collaborator

Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Los Angeles Biomedical Research Institute

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Loren G Miller, M.D., M.P.H.

Role: PRINCIPAL_INVESTIGATOR

Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Cedars-Sinai Medical Center

Los Angeles, California, United States

Site Status

Harbor-UCLA Medical Center

Torrance, California, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

NIH-AI01831

Identifier Type: -

Identifier Source: secondary_id

10024-05

Identifier Type: -

Identifier Source: org_study_id